Integrated HIV Testing, Malaria, and Diarrhea Prevention Campaign in Kenya: Modeled Health Impact and Cost-Effectiveness

James G. Kahn1*, Nicholas Muraguri2, Brian Harris1, Eric Lugada3, Thomas Clasen4, Mark Grabowsky5, Jonathan Mermin6, Shahnaaz Shariff2

1 Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, California, United States of America, 2 Ministry of Public Health and Sanitation, Government of Kenya, Nairobi, Kenya, 3 CHF International, Nairobi, Kenya, 4 London School of Hygiene & Tropical Medicine, London, United Kingdom, 5 ESP/UN Foundation, Washington, D.C., United States of America, 6 Coordinating Office for Global Health, CDC, Centers for Disease Control and Prevention-Kenya, Nairobi, Kenya

Abstract

Background: Efficiently delivered interventions to reduce HIV, malaria, and diarrhea are essential to accelerating global health efforts. A 2008 community integrated prevention campaign in Western Province, Kenya, reached 47,000 individuals over 7 days, providing HIV testing and counseling, water filters, insecticide-treated bed nets, condoms, and for HIV-infected individuals cotrimoxazole prophylaxis and referral for ongoing care. We modeled the potential cost-effectiveness of a scaled-up integrated prevention campaign.

Methods: We estimated averted deaths and disability-adjusted life years (DALYs) based on published data on baseline mortality and morbidity and on the protective effect of interventions, including antiretroviral therapy. We incorporate a previously estimated scaled-up campaign cost. We used published costs of medical care to estimate savings from averted illness (for all three diseases) and the added costs of initiating treatment earlier in the course of HIV disease.

Results: Per 1000 participants, projected reductions in cases of diarrhea, malaria, and HIV infection avert an estimated 16.3 deaths, 359 DALYS and $85,113 in medical care costs. Earlier care for HIV-infected persons adds an estimated 82 DALYs averted (to a total of 442), at a cost of $37,097 (reducing total averted costs to $48,015). Accounting for the estimated campaign cost of $32,000, the campaign saves an estimated $16,015 per 1000 participants. In multivariate sensitivity analyses, 83% of simulations result in net savings, and 93% in a cost per DALY averted of less than $20.

Discussion: A mass, rapidly implemented campaign for HIV testing, safe water, and malaria control appears economically attractive.

Introduction

The potential role of cost-effectiveness analysis in global health decision-making is increasingly recognized [1]. Interventions vary substantially in their ability to deliver health value per amount expended. The value of global health spending can be maximized by prioritizing cost-effective interventions [2].

Differences in cost-effectiveness reflect several factors: the prevalence and severity of disease, the protective effect offered by interventions, and — the only factor substantially under operational control — how efficiently services are delivered. Innovations in delivery strategies may offer substantial savings in cost per person served, as well as greater coverage. These strategies may include a community or health facility focus, as well as streamlining of health care processes [3–5]. They can include multiple disease interventions delivered simultaneously, offering the potential to share fixed costs (such as reaching into communities) while addressing multiple high disease burdens. However, little attention has been paid to the economics of multi-disease intervention delivery.

In a separate report, we examined the cost of a multi-disease 7-day integrated prevention campaign (IPC) in Western Province, Kenya, that was implemented in 2008 in 30 village centers [6,7]. The IPC provided HIV testing and counseling, water filters, insecticide-treated bed nets, condoms, and for HIV-infected individuals CD4 count enumeration, 3 months of cotrimoxazole, and referral to care. Ongoing community mobilization, including
health education, was conducted during the campaign, as well as in the preceding month. More than 40,000 (80%) of targeted adults were reached [6]. Full details of the campaign have been published previously [6]. We calculated a cost of $12 per person served for this initial implementation. We further estimated a cost of $32 per person for a scaled-up campaign relying fully on Kenyan staff and using a leaner management structure, as shown possible in a subsequent campaign [7]. The unit cost per person for the scaled-up campaign was estimated to be $6.27 for malaria (nets, education, and training), $15.90 ($2.55 per person-year) for diarrhea (filters, education, and training), and $9.92 for HIV (test kits, counseling, condoms, education, and CD4 testing). These estimated costs compare favorably with prior unit costs of bed nets ($6–27 [8–10], filters ($3 per person-year) [11], and HIV VCT ($7–101) [5,12–16].

The cost-effectiveness of these interventions, delivered separately, has been assessed – for example, bed nets $14–42 per disability-adjusted life year (DALY) averted [8,17], filters $142 per DALY averted [11], and HIV testing $15–18 per DALY averted [13]. The cost-effectiveness of these interventions delivered in combination is unknown. However, provision of a multi-disease intervention package including ART, cotrimoxazole prophylaxis, and bed nets has been shown to provide synergistic benefits for AIDS and malaria [18,19]. To provide further information for policy makers, we estimated the health impact and cost-effectiveness of delivering an integrated, community-level, multi-disease prevention campaign in rural Kenya.

Methods

Overview
We estimated the health impact, cost, and cost-effectiveness of the integrated multi-disease prevention campaign using a spreadsheet-based model constructed for this purpose. We relied on a post-campaign survey to confirm high coverage in the district and to estimate the number of individuals directly benefitting from distributed commodities. We derived baseline morbidity and mortality from regional and local epidemiologic data, and estimated the protective effects of interventions from published community trials. We estimated disability-adjusted life years (DALYs) based on reductions in life years lost to mortality and in illness episodes, weighted by published disability levels. We incorporated an estimated campaign cost of $32 per participant based on financial records and adjustments for scale-up (reported separately and summarized here). Finally, we used published data on costs of health care to estimate savings due to averted disease and added costs due to earlier HIV treatment.

Model structure

The model was constructed for this analysis in a spreadsheet (Excel, Microsoft Corporation, 2002). The model portrays health benefits and averted costs due to averted disease separately for malaria (due to long-lasting impregnated nets (LLIN)), diarrhea (due to filters), and HIV (due to voluntary counseling and testing (VCT) and condoms). Since these conditions are predominantly unrelated (i.e., in different individuals), we assume independence, which is conservative since interdependence would amplify the health impact of interventions. We used the following calculations:

$$\text{DALYs averted} = N \times B \times (F \times D_f \times P_f + (1-F) \times D_n \times P_n) \times M \times Y$$

Where:
- $N$ = number who benefit per campaign participant
- $B$ = baseline cases of this disease per year per individual benefiting
- $F$ = proportion of cases that are fatal
- $D_f$ = DALYs incurred with each fatality
- $P_f$ = protective effect against mortality
- $D_n$ = DALYs incurred with each non-fatal case
- $P_n$ = protective effect against non-fatal cases
- $M$ = multiplier to capture secondary benefits
- $Y$ = duration of benefit (in years)

The model also estimates the health and cost effects of changed level of use of anti-retroviral therapy (ART). The campaign accelerates use of ART through earlier detection of infected individuals, with a CD4 count closer to the recommended level for initiation of ART. It may also increase the lifetime use of ART by avoiding deaths prior to HIV diagnosis. This higher ART use extends life (thus averting DALYs), and adds costs. The campaign likely delays the use of ART by slowing the decline in CD4 count, through two mechanisms: prevention of malaria episodes, which cause drops in CD4 count; and distribution of cotrimoxazole, which slows CD4 decline. These delays in ART use extend life (averting DALYs) and also avert costs. Finally, we estimate the effect of the net changed time on ART on HIV transmission (which is suppressed by ART use).

Each calculation of the effect on ART use requires several types of inputs: biological factors (e.g., CD4 count at detection of infection, and rates of CD4 decline), intervention effects (e.g., cotrimoxazole effect on rate of CD4 decline), and behaviors (e.g., starting ART if referred). Key input values are presented below. Calculation methods are presented in a technical supplement posted online (Supporting Information S1) and available from the authors.

Data inputs

Table 1 presents data inputs, with base case values and sources, for the malaria, diarrhea, and HIV prevention analyses. Table 2 presents key data inputs, values, and sources for the analysis of HIV treatment and health status.

Health inputs. The number of individuals who benefit per campaign participant for malaria and diarrhea reflects a mean of 2.5 participants per household and 7.7 members per household respectively (both derived from the post-campaign survey). Thus, a mean of 3.1 (± 7.7/2.5) individuals benefit per campaign participant. This number is lower for malaria (2.9) due to bed nets obtained from non-campaign sources. For HIV, the number benefitting per participant (0.95) is the proportion that were HIV tested, and the number benefitting from condoms (0.36) reflects the percent of participants reporting use of campaign-distributed condoms.

The baseline cases of disease per individual derive from published estimates for sub-Saharan Africa and studies conducted in nearby geographic areas (e.g., Uganda). We estimate 0.3 malaria episodes [18,20] and 1.75 diarrhea episodes [21–24] per person per year. For HIV, estimated annual risk per campaign participant from persons found HIV-positive to others is 0.0038,
based on a conservative annual transmission risk of 8% [25] and 4.7% prevalence, from the post-campaign survey and consistent with a national AIDS survey [26]; and to persons found HIV-negative is 0.009, based on HIV incidence imputed from prevalence with assumption of random mixing [27]. Fatality rates for malaria and diarrhea are less than 1% (for all ages, occurring mostly in children) [20–24], and for HIV is 100% (over 10 or more prevalence with assumption of random mixing [27]). The protective effect of bed nets against malaria mortality is set at 50% (the same as for incidence). This is a conservative estimate based on a 17% reduction in all-cause mortality [30] and malaria representing only 9% of mortality <14 years old [24]. The protective effect of filters on diarrhea is 63% for morbidity [11], and we assume the same for mortality. For HIV, by “death averted” we mean an infection averted. The protection from VCT is conservatively 50% (in positives only) [31] and by condoms is 26% (in negatives only, among the 36% using the condoms, based on the number of condoms provided and 80% protection when a condom is used) [32]. For HIV, each infection averted is assumed to directly avert an average of one additional HIV infection in an epidemic with stable HIV prevalence; this would be a secondary benefit of the HIV interventions in the IPC. To capture this benefit we included a multiplier, which we conservatively set at 2 for HIV, confirmed with analyses using our published epidemic model, which predicts a 2.0 multiplier after 10 years [33].

The duration of benefit for bed nets is 3 years [10,35], and for filters is estimated at 2 years (less than lab data imply) [36]. For HIV risk reduction, one year of benefit is assumed for VCT, reflecting the longest duration of follow-up reported in a recent systematic review [31]. For condoms, we also employed a one-year time frame, using the number of distributed condoms to calculate the incremental probability of protected sex episodes over one year.

For the analysis of earlier use of ART, assumptions were as follows (key inputs reported in Table 2). In the campaign, 13 of 88 (14.8%) of a sample of individuals testing positive had a CD4 count less than 250, a commonly used starting level for ART. (We explore the effect of starting ART at CD4<350 through sensitivity analysis). We

| Table 1. Value of model inputs for prevention, Integrated Prevention Campaign, Western Province, Kenya, 2008. |

| Health inputs | Malaria | Diarrhea | HIV | Source(s) |
|----------------|---------|----------|-----|------------|
| N number who benefit per campaign participant | 2.9 | 3.1 | 0.95 | 0.36 | Post-campaign survey | Post-campaign survey | Post-campaign survey |
| B baseline cases of this disease per year per individual benefiting | 0.30 | 1.75 | 0.0038 | 0.009 | [18,20] | [21–24] | [25–27], Post-campaign survey (see text) |
| F proportion of cases that are fatal | 0.0033 | 0.0010 | 1.0 | 1.0 | [20,22] | [21–24] | Assumption |
| Df DALY’s incurred with each fatal case | 30 | 30 | 8 | 8 | [24] | [24] | [29] |
| Dnf DALY’s incurred with each non-fatal case | 0.0037 | 0.0020 | n/a | n/a | [24], expert opinion | [24,28] | N/a |
| Pf protective effect against mortality | 0.50 | 0.63 | 0.50 | 0.26 | [30], expert opinion | [31] | N/a |
| Mn multiplier to capture secondary benefits | n/a | n/a | 2 | 2 | [34] | N/a | [33] (see text) |
| $\gamma$ duration of benefit (in years) | 3 | 2 | 1 | 1 | [10,35] | [36] | [31] |

| Cost inputs | Malaria | Diarrhea | HIV | Source(s) |
|----------------|---------|----------|-----|------------|
| $C_t$ costs for health care incurred with each fatality | $65$ | $104$ | $5,092$ | $5,092$ | [40,41] | [42] | [29] (see text) |
| $C_n$ costs for health care incurred with each non-fatal case | $7.80$ | $7.00$ | n/a | n/a | [43] | [42] | N/a |

doi:10.1371/journal.pone.0031316.t001

doi:10.1371/journal.pone.0031316.t002

The duration of benefit for bed nets is 5 years [10,35], and for filters is estimated at 2 years (less than lab data imply) [36]. For HIV risk reduction, one year of benefit is assumed for VCT, reflecting the longest duration of follow-up reported in a recent systematic review [31]. For condoms, we also employed a one-year time frame, using the number of distributed condoms to calculate the incremental probability of protected sex episodes over one year.

| Table 2. Value of model inputs for treatment and health status in HIV+ individuals, Integrated Prevention Campaign, Western Province, Kenya, 2008. |

| Value | Sources |
|-------|---------|
| $Re$ Seek ART care early | 0.60 | [26], expert opinion |
| $Ai$ Lifetime increase in use of ART due to IPC | 0.15 | Expert opinion |
| $Ma$ Malaria cases averted by LLIN per HIV+ person | 0.6 | [18,30] |
| $Ca$ CD4 drop averted per malaria event averted (absolute) | 40 | [19] |
| $Cr$ Reduction in CD4 drop with CTX (proportionate) | 0.62 | [39] |
| $H$ HIV infections transmitted per year not on ART | 0.05 | [27,31] |

doi:10.1371/journal.pone.0031316.t002
assumed that 60% of these individuals sought ART care quickly, conservatively one year before they would have otherwise [26]. We estimated the resulting averted DALYs at 0.75, from clinical modeling studies [37,38]. Lifetime increased use of ART due to the IPC (e.g., by avoiding death before HIV diagnosis) is estimated at 15%, based on expert opinion (author JM) considering current and projected lifetime prevalence of ART use. Each additional person on ART averts 7.5 DALYs (discounted, over a lifetime) [29]. Bed nets may delay the need for ART by reducing episodes of malaria, which have been associated with an average 40 point decline in CD4 [19]. This results in an approximately one-third year delay to need ART. Cotrimoxazole also may delay the need for ART, based on a study showing a 62% reduction in the rate of decline of CD4 [39]. We apply this reduction after the protection afforded by bed nets, resulting in a further 0.49 year delay in starting ART.

The aggregate effects of the earlier, increased, and delayed ART use described above is 15.1 added years not on ART per 1000 campaign participants. This increases HIV transmission by an estimated 0.75 infections per 1000 participants (separate from the HIV prevention effects discussed above). Technical details related to our modeling of the impact of the IPC on HIV treatment are included in a technical supplement (see Supporting Information S1).

Cost inputs. We estimated the costs for health care incurred with each malaria and diarrhea fatality based on the direct medical costs of inpatient treatment for each disease, assuming that fatal cases are likely to use inpatient care. The cost of health care (Table 1) is estimated at $65 per fatality for malaria [40,41] and $104 for diarrhea [42]. For HIV, the costs of health care per fatality are estimated at $592, based on a 2009 analysis of lifetime costs adjusted for lower annual ART costs (C223) in Zambia in a current analysis [29]. For non-fatal cases, the costs are $7.80 per case for malaria (using a relatively expensive drug, co-artem) [43] and $7 for diarrhea [42], for each assuming outpatient treatment, including the cost of a clinic visit, medications and tests.

The cost of a scaled-up IPC is estimated at $32 per participant [7]. The original campaign cost $42 per participant. A scaled-up campaign will have lower costs through reliance on local rather than foreign managers and a lower manager concentration, as well as returns to scale for the publicity component. These adjustments were initially modeled, and then confirmed in a small subsequent campaign and with price bids for a large campaign [7].

Sensitivity analyses

We conducted one-way and multivariate sensitivity analyses to assess the importance of uncertainty in input values. To set the uncertainty ranges, we used a 95% confidence interval (CI) when available. For values based directly on empirical data but lacking formal CIs, we used a range of plus or minus one-third of the base case. For values derived indirectly from empirical data or from expert opinion, we used a range of plus or minus one-half. For DALYs due to early death for malaria and diarrhea, we examine down to 25 to reflect potential short-term competing mortality.

The multivariate analysis was a Monte Carlo simulation conducted with Crystal Ball, Decision Engineering © 2000. We used the reported ranges distributed in truncated normal curves. We assumed a 95% correlation of this variable with lifetime cost of treating HIV. Simulation results reflect 100,000 trials.

Results

Disease averted

The model estimates that the IPC averts 16.3 deaths: 4.31 from malaria, 6.81 from diarrhea, and 5.22 from HIV. There are an additional 1304 averted episodes of malaria and 6780 of diarrhea.

DALYs averted

The prevention elements of the campaign avert an estimated 359 DALYs per 1000 participants (Table 3). Most of these benefits (53%) derive from decreased diarrhea, due to the protective effect from relatively frequent disease episodes. Reduced malaria accounts for 35% of averted DALYs, and HIV prevention 12%.

Reduced mortality contributes the vast majority (96%) of DALYs averted through prevention. Though rare, prevented deaths avert

Table 3. Results (per 1000 campaign participants), Integrated Prevention Campaign, Western Province, Kenya, 2008.

| Disease averted        | Malaria | Diarrhea | HIV |
|------------------------|---------|----------|-----|
|                         | LLIN    | Filters  | VCT | condoms |
| Deaths                  | 4.31    | 6.81     | 5.22|         |
| Episodes                | 1304    | 6780     | 5   |          |
| DALYs averted           | 125     | 191      | 29  | 13       |
|                        | 125     | 191      | 82  | 125      |
| TOTAL                  | 125     | 191      | 82  | 125      |
| Costs averted (added)   | 10,420  | 48,123   | 18,169 | 8,400 |
|                         | 13,097  | (37,097) | (37,097) |
| TOTAL                  | 10,420  | 48,123   | (10,538) |
| $10,420                 | $48,123 | $18,169  | $8,400 | $58,113|
| $85,113                 |         |          |      |

Cost-effectiveness

Campaign cost (unadjusted) $32,000
Net cost (savings) $16,015
Cost per DALY averted Net savings

doi:10.1371/journal.pone.0031316.t003
Thus, overall savings are 10,000-fold as many DALYs each as do non-fatal disease clinical events. Earlier HIV care results in a net of 83 averted DALYs. Thus total DALYs averted is estimated at 442 per 1000 campaign participants, 78% of which is from deaths averted.

Costs averted
The savings due to prevented disease are $85,113 per 1000 participants. The contribution of HIV disease is 31%, much larger than for DALYs due to the high lifetime cost of treatment. Diarrhea and malaria contribute 57% and 12%, respectively.

Earlier HIV care (ART) increases costs by nearly $37,100. Thus, overall savings are $48,015.

Cost-effectiveness

The estimated campaign cost of $32,000 is less than the savings projected by our model. Thus, in the base case, the campaign is estimated to result in net savings of $16,015 per 1000 participants. With net savings, the incremental cost-effectiveness ratio (ICER) is not reported; an ICER is reported as appropriate in sensitivity analyses. The ICER based on gross costs (unadjusted for offsetting savings) is $72 per DALY averted.

Table 4. One-way sensitivity analyses for health inputs, Integrated Prevention Campaign, Western Province, Kenya, 2008.

| Health inputs: Prevention | Range used for input | DALYs averted | Net cost (savings) | Cost per DALY averted |
|---------------------------|----------------------|---------------|--------------------|----------------------|
| **N** who benefit per campaign participant | Malaria (LLIN) | 1.9–3.9 | 399–485 | ($12,436–$19,622) | Net savings |
| Diarrhea (filters) | 2.1–4.1 | ±1/3 | 381–505 | ($629–$31,808) | Net savings |
| HIV - VCT | 0.9–1.0 | ±0.05 | 441–444 | ($15,057–$16,969) | Net savings |
| HIV - condoms | 0.24–0.48 | ±1/3 | 438–446 | ($13,196–$18,779) | Net savings |
| **B** baseline cases/year per 1000 persons | Malaria | 200–400 | 400–484 | ($12,540–$19,486) | Net savings |
| Diarrhea | 1200–2300 | ±1/3 | 382–502 | ($889–$31,137) | Net savings |
| HIV transmission | 2.5–5.1 | ±1/3 | 433–452 | ($9,933–$22,508) | Net savings |
| HIV acquisition | 6–12 | ±1/3 | 438–447 | ($13,238–$18,862) | Net savings |
| **F** proportion of cases that are fatal | Malaria | 0.22–0.44% | 402–482 | ($15,930–$16,095) | Net savings |
| Diarrhea | 0.05–0.15% | ±1/3 | 353–532 | ($15,683–$16,343) | Net savings |
| **D** DALYs incurred with each fatal case | Malaria | 25 (lower) see text | 429 - BC | = BC | Net savings |
| Diarrhea | 25 (lower) see text | 423 - BC | = BC | Net savings |
| HIV | 4–12 | ±1/2 | 424–460 | = BC | Net savings |
| **D** DALYs incurred with each non-fatal case | Malaria | 0.0019–0.0055 | 439–444 | = BC | Net savings |
| Diarrhea | 0.001–0.003 | ±1/2 | 435–448 | = BC | Net savings |
| **P** protective effect against mortality | Malaria | 0.25–0.75 | 382–502 | ($15,837–$16,153) | Net savings |
| Diarrhea | 0.32–0.94 | ±1/2 | 354–530 | ($15,664–$16,361) | Net savings |
| HIV transmission | 0.25–0.75 | ±1/2 | 428–456 | ($6,929–$35,103) | Net savings |
| HIV acquisition | 0.13–0.39 | ±1/2 | 435–449 | ($11,900–$20,467) | Net savings |
| **P** protective effect against non-fatal cases | Malaria | 0.33–0.67 | 440–443 | ($12,569–$19,468) | Net savings |
| Diarrhea | 0.51–0.72 | 95% CI | 439–444 | ($7,125–$22,989) | Net savings |
| **M** multiplier to capture secondary benefits | HIV | 1–3 | ±1/2 | 421–463 | ($2,728–$29,298) | Net savings |
| **Y** duration of benefit (in years) | Malaria | 2–4 | ±1/3 | 400–484 | ($12,540–$19,487) | Net savings |
| Diarrhea | 1.3–2.7 | ±1/3 | 375–509 | $824–$32,869 | $2.20 - net savings |
| HIV transm. | 0.5–1.5 | ±1/2 | 421–463 | ($2,727–$29,298) | Net savings |

Sensitivity analyses

We conducted univariate and multivariate sensitivity analyses. The univariate sensitivity analyses assessed the importance of uncertainty in individual model inputs (Tables 4, 5 and 6). DALYs averted per 1000 participants ranged from 338 to 543. For the 37 inputs assessed, 35 retained net savings for all values; one had a net cost per DALY averted of $0.30, and two had net cost per DALY averted over $1.00: $2.20 and $17.42. The inputs with the largest impact on net costs were the lifetime increase in the use of ART ($32,169 in savings to $143 in added cost); the frequency, magnitude, and duration of benefit for diarrhea; the prevention multiplier and duration of benefit for HIV; and cost per non-fatal diarrhea case.

Uncertainty in baseline cases per 1000 persons (i.e., disease incidence) showed the greatest sensitivity for diarrhea ($889 to $31,137 in net savings), followed by HIV and then malaria (Table 4). The proportion of cases that are fatal for malaria and diarrhea had little effect, and DALYs incurred per fatal and non-fatal case also did not affect findings significantly.

Protective effect against mortality strongly affected DALYs but not costs. Even with no mortality benefit for diarrhea, as found in a trial of safe water vessels in the context of weekly clinical
monitoring [44], there would be 263 DALYs averted, with net savings of $15,305 (not in table). Protective effect against non-fatal cases has a moderate impact for diarrhea: 51% protection leads to $90 per 1000 participants was mean 442 (standard deviation 78), median 435, 90% confidence interval 327–583, and range 245–7,125 net savings.

The sensitivity of net cost and cost per DALY averted to campaign implementation cost and protective effect are shown graphically in Figures 1 and 2. The net cost increases as campaign cost rises, but remains negative until the campaign cost reaches $18,000 per 1000 participants (Fig. 1). For the interventions’ protective effect, the net cost becomes positive below 0.81 of base case values, and reaches a cost per DALY averted of $60 at 0.6 of base case (Fig. 2).

Due to expanded support for starting ART at CD4<350, we examined the implications of the higher threshold. The effects of earlier ART initiation are modest: DALYs averted increases to 443, and savings drops to $15,539.

Our multivariate analysis (Monte Carlo simulation) suggests that the most likely outcome is substantial health impact with net savings, with only 17% of trials (i.e., calculation iterations) yielding modest costs per DALY averted. The estimated DALYs averted per 1000 participants was mean 442 (standard deviation 78), median 435, 90% confidence interval 327–583, and range 245–641. The mean net savings was $16,102 (median $15,306). The 90% CI was savings of $45,579 to added cost of $154,658 net savings. The estimated health benefit of 442 disability-adjusted life years averted, with a net savings of approximately $16,000. The prevention component yielded 81% of the DALYs averted and large net savings ($35,113). Earlier HIV care yielded additional DALYs and also substantial net costs, due to the high cost of ART. Multivariate sensitivity analyses suggest that overall health benefits reside between 327 and 583 DALYs, the campaign is cost-saving for more than four-fifths of simulation trials, and the cost per DALY averted is less than $20 for 93% of trials.

Compared with the cost-effectiveness of individual interventions, these results are generally more favorable. Malaria interventions cost in the range of $2–15 per DALY averted even for the least expensive strategies [1]. Diarrhea prevention has ten- to 100-fold higher cost-effectiveness ratios; filters alone are estimated at $142 per DALY averted [11]. HIV prevention is undefined at the mean (due to net savings in most trials), was less than $20 for 93% of trials, and reached a high of $65 per DALY. Graphic results of the multivariate analysis are included in a technical supplement (see Supporting Information S2).

### Discussion

We explored the potential health impact, net cost, and cost-effectiveness of an integrated mass campaign to distribute commodities and services intended to decrease malaria, diarrhea, and HIV. We found, for each 1000 campaign participants, an estimated health benefit of 442 disability-adjusted life years averted, with a net savings of approximately $16,000. The prevention component yielded 81% of the DALYs averted and large net savings ($35,113). Earlier HIV care yielded additional DALYs and also substantial net costs, due to the high cost of ART. Multivariate sensitivity analyses suggest that overall health benefits reside between 327 and 583 DALYs, the campaign is cost-saving for more than four-fifths of simulation trials, and the cost per DALY averted is less than $20 for 93% of trials.

### Table 5. One-way sensitivity analyses for cost inputs, Integrated Prevention Campaign, Western Province, Kenya.

| Cost inputs | Range used for input | DALYs averted | Net cost (savings) | Cost per DALY averted |
|-------------|----------------------|---------------|--------------------|-----------------------|
| Values      | Basis                |               |                    |                       |
| $ C_f $ costs for health care per fatality | Malaria $33–$379 | $ ±1/2$ Be BC | ($16,015) | Net savings |
| $ D_f $ costs for health care per non-fatal case | Malaria $3.90–$11.70 | $ ±1/3$ Be BC | ($10,943)–($21,083) | Net savings |
| $ C_r $ cost of campaign | - | $ ±1/10$ Be BC | ($19,215)–($21,815) | Net savings |
| $ C_c $ cost of campaign | - | $ ±1/10$ Be BC | ($19,215)–($21,815) | Net savings |

Note: BC = base case.

### Table 6. One-way sensitivity analyses for inputs on treatment and health status in HIV-positive individuals, Integrated Prevention Campaign, Western Province, Kenya.

| Treatment and health status in HIV+ individuals | Range used for input | DALYs averted | Net cost (savings) | Cost per DALY averted |
|------------------------------------------------|----------------------|---------------|--------------------|-----------------------|
| Values | Basis |               |                    |                       |
| $ A_e $ Seek ART care early | HIV | $0.3–0.9$ | $ ±1/2$ | $439–444$ | ($16,015)–($15,368) |
| $ A_i $ Lifetime increase in use of ART due to IPC | HIV | $0.075–0.225$ | $ ±1/2$ | $413–471$ | ($32,169)–($1,143) |
| $ M_a $ Malaria cases averted by LLIN per HIV+ person | Malaria-HIV | $0.4–0.8$ | $ ±1/3$ | $441–443$ | ($16,240)–($15,889) |
| $ C_a $ CD4 drop averted per morbid event averted | HIV | $13–68$ | $95% CI | $440–443$ | ($16,240)–($15,750) |
| $ C_r $ Reduction in CD4 drop with CTX | HIV | $0.335–0.905$ | $95% CI | $436–447$ | ($16,962)–($15,053) |
| $ H $ HIV infections transmitted per year not on ART | HIV | $0.025–0.075$ | $ ±1/2$ | $431–437$ | ($38,848)–($23,200) |
| $ A_c $ Annual cost of ART | HIV | $282–$846 | $ ±1/2$ | $65 per DALY. |

Note: BC = base case.

Note: BC = base case.
often cost saving, due to the high cost of care, with savings exceeding costs by 25- to 30-fold [33,45]. HIV care with ART costs $500–$800 per DALY averted in Africa [29,46], and CD4 cell and viral load monitoring of ART $174 and over $5000 per DALY averted, respectively [47].

Our analysis had several limitations. As with many cost-effectiveness analyses, health impacts and averted care costs are modeled rather than measured directly for the campaign. However, empirical studies of similar interventions have shown evidence of effectiveness in reducing morbidity and mortality over specified time periods, which we adopted and use as the basis for the modeled prevention benefits from the IPC. By including the best available input values and a diversity of inputs (e.g., protective effects for three diseases) we have mitigated this limitation. Further, robust sensitivity analyses allowed us to assess uncertainty in effectiveness, with favorable findings over the range of values explored.

Second, the campaign cost is based on an economic model for scaling up, and is 25% lower than the cost of the initial campaign implementation. We think that uncertainty in this cost estimate is low, based on confirmatory data from subsequent campaign implementation and planning, and thus has little effect on our findings. However, it will be important to observe actual costs in a scaled up implementation. Repeat campaigns in the same
geographical location would yield a lower number of new HIV diagnoses, and depending on timing in relation to commodity life spans could yield lower participation and/or health benefits. Finally, we did not explore savings by linking this campaign to other community campaigns, such as annual mass vitamin A administration [48] or regular indoor residual spraying (IRS) against malaria. We did not include the effect of earlier ART on tuberculosis (TB). Co-infection of HIV and TB approaches 50% in Kenya [49], and ART may reduce TB acquisition by greater than 60%, depending on when treatment is initiated [50]. This might suggest substantial health gains and economic savings via TB control due to expanded use of ART. In addition, earlier TB diagnosis might lead to easier treatment. However, other factors complicate this picture. Some TB infection that would be detected and treated while under care would never have become clinically significant. Further, ART may induce clinical worsening of TB, due to immune reconstitution (Robin Wood, personal communication). We believe that in the long run, expanded ART will reduce TB transmission and thus prevalence, but in the short run the effects are difficult to anticipate.

This analysis supports a substantial role for integrated multi-disease mass campaigns. Such campaigns are potentially very practical, quickly achieving high coverage of key interventions to reduce the burden of three major diseases, with substantial health benefits, and attractive economics. The campaigns would need to be repeated over time in order to offer ongoing benefits. The optimal timing is unclear, due to the differing duration of campaign interventions: up to ten years for LLIN, three years for water filters, and one year for VCT and condoms. In addition, newly detected HIV cases will drop sharply after the initial implementation, since HIV incidence is much lower than undetected HIV prevalence. Optimal timing would also reflect the local availability of these services through other mechanisms. On balance, we suspect that a three-year cycle would be desirable in most settings. We plan to formally assess this issue in an upcoming analysis.

In conclusion, we propose expanded field implementation of integrated multi-disease mass campaigns, coupled with rigorous evaluation and refinement.

Disclaimer

The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention.

Supporting Information

Supporting Information S1 Technical Supplement 1. Technical details regarding modeling of the impact of the campaign on HIV treatment. (DOC)

Supporting Information S2 Technical Supplement 2. Technical details regarding Monte Carlo multi-variate sensitivity analyses. (DOC)

Author Contributions

Conceived and designed the experiments: JGK. Analyzed the data: JGK BH. Wrote the paper: JGK BH EL TC JM SS MG NM.

References

1. Laxminarayan R, Mills AJ, Berman JG, Marshall AR, Alleyne G, et al. (2006) Advancement of global health: key messages from the Disease Control Priorities Project. Lancet 367: 1193–1208.
2. Jamison DT (2006) Investing in Health. In: Jamison DT, ed. Disease Control Priorities in Developing Countries (2nd ed). New York: Oxford University Press and the World Bank.
3. Grabowsky M, Nobiya T, Abun M, Donna R, Lengeler M, et al. (2005) Distributing insecticide-treated bednets during measles vaccination: a low-cost means of achieving high and equitable coverage. Bull World Health Organ 83: 195–201.
4. Grabowsky M, Nobiya T, Selankio J (2007) Sustained high coverage of insecticide-treated bednets through combined Catch-up and Keep-up strategies. Trop Med Int Health 12: 815–822.
5. Menzies N, Abang B, Wanyenze R, Nuwaha F, Mugisha B, et al. (2009) The costs and effectiveness of four HIV counselling and testing strategies in Uganda. AIDS 23: 395–401.
6. Lugada E, Miller D, Haskew J, Grabowsky M, Garg N, et al. (2010) Rapid implementation of an integrated large-scale HIV counseling and testing, and malaria prevention campaign in rural Kenya. PLoS One 5: e12435.
7. Kahn J, Harris B, Mermin J, Clasen T, Lugada E, et al. (2010) Cost of Integrated Community Prevention Campaign for Malaria, HIV, and Diarrhea in Rural Kenya. BMC Health Serv Res. In press.
8. Mueller DH, Wiseman Y, Bakana D, Morgah K, Dare A, et al. (2008) Cost-effectiveness analysis of insecticide-treated net distribution as part of the Togo Integrated Child Health Campaign. Malar J 7: 73.
9. Yukić JO, Lengeler C, Tediosi F, Brown N, Mugisha B, et al. (2008) Costs and consequences of large-scale vector control for malaria. Malar J 7: 258.
10. Mulligan JA, Yukić J, Hanso K (2008) Costs and effects of the Tanzanian national voucher scheme for insecticide-treated nets. Malar J 7: 32.
11. Clasen T, Haller L, Walker D, Bartram J, Cairncross S (2007) Cost-effectiveness of water quality interventions for preventing diarrhoeal disease in developing countries. J Water Health 5: 599–608.
12. McNicol CE, Stanley N, du Plessis J, Pitter CS, Ashbula F, et al. (2005) The cost of a rapid-test VCT clinic in South Africa. S Afr Med J 95: 968–971.
13. Sweat M, Gregorich S, Sangiwa G, Furlonge C, Balmer D, et al. (2000) Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania. Lancet 336: 113–121.
14. Fosythe S, Arthur G, Njiga T, Obwangi R, Olthaberujo J, et al. (2002) Assessing the cost and willingness to pay for voluntary HIV counselling and testing in Kenya. Health Policy Plan 17: 187–195.
15. Hauser PH, Sinanovic E, Kumaranayake L, Naidoo P, Schoeman H, et al. (2006) Costs of measures to control tuberculosis/HIV in public primary care facilities in Cape Town, South Africa. Bull World Health Organ 84: 528–536.
16. Poirier JC, Dondona L, Marshall N, Gant P, Bastiaans-Arratundu S, et al. (2007) HIV prevention costs and program scale: data from the PANCEA project in five low and middle-income countries. BMC Health Serv Res 7: 108.
17. Morrell CM, Lauer JA, Evans DB (2005) Cost effectiveness analysis of strategies to combat malaria in developing countries. BMJ 331: 1299.
18. Mermin J, Ekwaru JP, Liechty CA, Were W, Dowming R, et al. (2006) Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 367: 1256–1261.
19. Mermin J, Lule JR, Ekwaru JP (2008) Association Between Malaria and CD4 Cell Count Decline Among Persons With HIV. J Acquir Immune Defic Syndr 41: 129–130.
20. Snow RW, Craig MH, Newton CRJ, Steketee RW (2003) The public health burden of Plasmodium falciparum malaria in Africa: Deriving the numbers. Working Paper No. 11. Bethesda, Maryland: Fogarty International Center, National Institutes of Health.
21. Crump JA, Otero PO, Shunkter L, Kosickic BH, Rosen DH, et al. (2005) Household based treatment of drinking water with flocculant-disinfectant for preventing diarrhoea in areas with turbid source water in rural western Kenya: cluster randomised controlled trial. BMJ 331: 478.
22. van Eijk AM, Adazu K, Ofware P, Valuile J, Hameel M, et al. (2008) Causes of deaths using verbal autopsy among adolescents and adults in rural western Kenya. Trop Med Int Health 13: 1314–1324.
23. Shrestha RK, Marselle E, Kahu JG, Lule JR, Pitter C, et al. (2006) Cost-effectiveness of home-based chlorination and safe water storage in reducing diarrhea among HIV-affected households in rural Uganda. Am J Trop Med Hyg 74: 884–890.
24. Lopez A (2006) Global Burden of Disease and Risk Factors. In: Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL, eds. Disease Control Priorities in Developing Countries (2nd ed). New York: Oxford University Press and the World Bank.
25. Grannich RM, Gins F, Dye C, De Cock KM, Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48–57.
28. Lever D, Soffer E (2011) Acute Diarrhea. Disease Management Project: Gastroenterology: The Cleveland Clinic Foundation, Center for Continuing Education.

29. Marseille E, Kahn JG, Pitter C, Bunnell R, Epalatai W, et al. (2009) The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy 7: 229–243.

30. Lengeler C (2004) Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev: CD000363.

31. Denison JA, O’Reilly KR, Schmid GP, Kennedy CE, Sweat MD (2008) HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990–2005. AIDS Behav 12: 363–373.

32. Weller S, Davis K (2002) Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev: CD000355.

33. Kahn JG, Marseille E, Auvert B (2006) Cost-effectiveness of male circumcision for HIV prevention in a South African setting. PLoS Med 3: e517.

34. Smith DL, Cohen JM, Mosonen B, Tatem AJ, Sabo OJ, et al. (2011) Infectious disease: Solving the Syphilis problem of malaria in Zanzibar. Science 332: 1384–1385.

35. Kilian A, Byamukama W, Pigeon O, Atieli F, Duchon S, et al. (2008) Long-term field performance of a polyester-based long-lasting insecticidal mosquito net in rural Uganda. Malaria journal 7: 49.

36. Claess T, Naranjo J, Frauchiger D, Gerba C (2009) Laboratory assessment of a gravity-fed ultrafiltration water treatment device designed for household use in low-income settings. Am J Trop Med Hyg 80: 819–823.

37. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, et al. (2008) Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med 168: 1910–1918.

38. Weller S, Davis K (2002) Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev: CD000355.

39. Kahn JG, Marseille E, Moore D, Bunnell R, Were W, et al. (2011) CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. BMJ 341: d6804.

40. Masanja H, Schellenberg JA, Mshinda HM, Shekar M, Mugabauso JK, et al. (2006) Vitamin A supplementation in Tanzania: the impact of a change in programmatic delivery strategy on coverage. BMC Health Serv Res 6: 142.

41. Organization WH (2009) WHO Report on Global Tuberculosis Control: Kenya. Geneva.

42. Williams BG, Granich R, De Cock KM, Glaziou P, Sharma A, et al. (2010) Antiretroviral therapy for tuberculosis control in nine African countries. Proceedings of the National Academy of Sciences of the United States of America 107: 19485–19489.